Semaglutide vs Tirzepatide: Mechanisms, Outcomes, and the Compounding Pharmacy Landscape

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The regulatory landscape for compounded medications changes frequently — verify current status with a licensed prescriber before making any decisions.

Semaglutide and tirzepatide have reshaped pharmacological weight management. Both are injectable compounds approved by the FDA. Both work through incretin hormone pathways. And both have been offered through compounding pharmacies — with a regulatory landscape that continues to shift. This post covers the mechanisms, the trial data, and the current 2026 provider availability picture based on live PeptideBase directory data.

---

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic molecule that mimics glucagon-like peptide-1, an incretin hormone produced in the gut after eating. It is FDA-approved under two brand names:

• Ozempic (2.0 mg/week max) — approved for type 2 diabetes management
• Wegovy (2.4 mg/week) — approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition

Its mechanism involves three primary actions: stimulating glucose-dependent insulin secretion, suppressing glucagon release to reduce liver glucose output, and — critically for weight management — slowing gastric emptying and activating GLP-1 receptors in the hypothalamus to reduce appetite and caloric intake.

Semaglutide has a half-life of approximately seven days, achieved through structural modifications including a C18 fatty diacid chain that enables reversible albumin binding. This extended half-life is what makes once-weekly dosing possible.

What is tirzepatide?

Tirzepatide is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. It is FDA-approved as:

• Mounjaro — approved for type 2 diabetes
• Zepbound — approved for chronic weight management

The addition of GIP receptor agonism adds a complementary mechanism. GIP independently enhances insulin secretion and modulates adipose tissue metabolism through pathways distinct from GLP-1. The combined effect produces meaningfully greater average weight reduction in clinical trials. Whether the GIP mechanism also contributes to improved tolerability — particularly less nausea — is an active area of research with mixed evidence to date.

---

Head-to-head: what the trial data shows

The SURMOUNT-5 trial (2025) provided the first direct randomised comparison of the two compounds at their maximum approved doses for weight management:

Tirzepatide consistently achieves greater weight reduction on average. However, individual response varies substantially — some patients respond better to semaglutide, and tolerability profiles differ. The SURMOUNT-5 comparison is at maximum approved doses; at lower doses or with slower titration schedules, the gap may narrow.

The SELECT trial established that semaglutide reduces major adverse cardiovascular events by ~20% in patients with cardiovascular disease regardless of diabetes status — a meaningful clinical differentiator that tirzepatide's outcomes data has not yet fully matched Lincoff et al., 2023.

---

Side effect profiles

Both compounds share a class-effect side effect profile driven by GLP-1 receptor activity:

Common (both): Nausea, vomiting, diarrhoea, constipation, reduced appetite. Most pronounced during dose escalation; typically attenuate over weeks to months. Slower titration significantly reduces severity.

Less common (both): Gastroparesis (delayed gastric emptying becoming pathological), pancreatitis, gallbladder disease, injection-site reactions.

Tirzepatide-specific consideration: The GIP component may modestly reduce nausea incidence compared to semaglutide at equivalent weight-loss efficacy doses — the mechanistic rationale is plausible, but the clinical evidence is mixed.

Contraindications (both): Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2. Both carry FDA black box warnings on thyroid C-cell tumour risk observed in rodent studies.

Muscle mass consideration: Both compounds produce weight reduction that includes lean mass alongside fat mass. Research into co-administration with GH-axis peptides (including sermorelin and ipamorelin) for lean mass preservation is ongoing, but this falls outside approved uses and should only be evaluated with a licensed prescriber.

---

The compounding pharmacy landscape (2026 update)

From 2022 through early 2025, compounded semaglutide and tirzepatide were widely available through 503A and 503B pharmacies in the United States. Compounding was legally permissible because both drugs appeared on the FDA's drug shortage list — a provision that allows compounding pharmacies to produce copies of shortage drugs under specific conditions.

The regulatory shift: The FDA removed semaglutide from the shortage list in early 2025, then tirzepatide followed. This triggered enforcement guidance stating that compounding of shortage-listed drug copies is no longer permissible once a drug exits the list. The result was widespread enforcement action against pharmacies and telehealth platforms still offering compounded versions.

What remains permissible in 2026:

503A compounding pharmacies may still compound semaglutide or tirzepatide in limited circumstances — for patients with documented clinical needs that the commercially available branded product cannot meet. Examples include specific dose strengths not available commercially, or documented allergies to inactive ingredients in the branded formulation. These are narrow carve-outs, not a general access pathway.

503B outsourcing facilities face stricter restrictions and are generally not producing compounded GLP-1 agonists for routine weight management in 2026.

The practical result: Branded Wegovy and Zepbound, obtained through a licensed prescriber, are the primary legal access pathway for most patients in 2026. Manufacturer patient assistance programs (Novo Nordisk and Eli Lilly both operate these) provide coverage pathways for uninsured or underinsured patients.

---

2026 provider availability — by the numbers

PeptideBase tracks which providers publicly list semaglutide and tirzepatide in their offerings. Based on current verified directory data (May 2026):

A few observations from the data worth noting:

Clinics dominate. Functional medicine clinics and weight management clinics are by far the largest provider category for both compounds. Many operate hybrid in-person/telehealth models.

503A pharmacy presence has contracted. The 50 semaglutide and 21 tirzepatide 503A pharmacy listings reflect the post-enforcement landscape — down significantly from pre-2025 availability. The remaining listings are pharmacies that either serve documented-clinical-need cases or have not yet updated their public listings.

Telehealth is concentrated, not widespread. Despite telehealth platforms being the most visible consumer-facing GLP-1 channel, only ~4% of PeptideBase's GLP-1 providers are pure telehealth platforms. Many of the clinic listings include telehealth delivery — the category breakdown reflects primary business model, not service delivery method.

---

Choosing between semaglutide and tirzepatide

This decision belongs with a licensed prescriber who knows your clinical picture. But the framework for thinking about it:

Lean toward tirzepatide if: Your primary goal is maximum weight reduction and you have no prior GLP-1 experience. The dual agonist mechanism consistently produces greater average outcomes in trial data. If you've tried semaglutide without adequate response, tirzepatide's different receptor profile may produce better results.

Lean toward semaglutide if: You have established cardiovascular disease — the SELECT trial's ~20% MACE reduction is a meaningful evidence-based differentiator that tirzepatide cannot yet match. Semaglutide also has a longer post-market safety record and wider prescriber familiarity.

Practical availability consideration: Semaglutide has ~51% wider provider coverage in the PeptideBase directory. If access or cost is a constraint, semaglutide is more likely to have a provider option within your geography and budget.

Insurance and cost: Wegovy and Zepbound are both expensive without coverage (~$1,000–$1,300/month list price). Both manufacturers operate patient assistance programs. Coverage decisions from payers are evolving — check your specific plan.

---

The prescription process — what to expect

For patients pursuing a legitimate GLP-1 prescription through a telehealth platform or clinic, the process typically looks like:

1. Intake questionnaire — health history, current medications, BMI, relevant conditions. Legitimate platforms require this before any clinical decision.
2. Prescriber review — a licensed practitioner reviews the intake and determines clinical appropriateness. Some platforms do this asynchronously; others schedule a live consultation.
3. Prescription issued — if appropriate, a prescription is written for a specific compound at a specific starting dose with a titration schedule.
4. Pharmacy fulfillment — for branded products, sent to a standard pharmacy. For any compounded formulation, sent to a licensed compounding pharmacy.
5. Ongoing monitoring — legitimate providers include follow-up protocols. Weight check-ins, side effect monitoring, dose adjustments. A provider with no follow-up process is not running a genuine clinical program.

The entire process from intake to first shipment typically runs 5–14 days for established telehealth platforms.

---

Finding licensed providers

Telehealth platforms and functional medicine clinics remain the primary access point for FDA-approved GLP-1 therapy under physician supervision.

• Semaglutide providers — 637 listed, filter by type and location
• Tirzepatide providers — 423 listed, filter by type and location
• Full provider directory
• Provider match quiz — 7-step questionnaire to find providers matched to your research goals

Always verify current regulatory status and prescription requirements with a licensed provider in your jurisdiction.

---

Frequently asked questions

QIs tirzepatide always more effective than semaglutide?

On average, yes — SURMOUNT-5 (2025) showed tirzepatide produces ~20–22% weight reduction vs ~15% for semaglutide at maximum approved doses. But individual response varies substantially. Some patients respond better to semaglutide, tolerability differs, and the cardiovascular outcomes evidence currently favours semaglutide for patients with established cardiovascular disease. Average trial data is a starting point for clinical discussion, not a prediction for any individual patient.

QCan I still get compounded semaglutide or tirzepatide in 2026?

In limited circumstances, yes. 503A pharmacies may still compound these drugs for patients with documented clinical needs the branded product cannot meet — specific dose strengths, or documented allergies to inactive ingredients. This is a narrow carve-out, not a general access pathway. Compounding for routine weight management without clinical justification is no longer permissible following FDA shortage-list removals. Verify current status with a licensed prescriber in your state.

QWhat do manufacturer patient assistance programs cover?

Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both operate patient assistance programs for uninsured or underinsured patients. Coverage and eligibility vary and change periodically — check the manufacturer's official website directly. These programs apply to branded products only and do not extend to compounded versions.

QWhy does semaglutide have more providers than tirzepatide?

Semaglutide entered the market earlier and had a longer compounding window before shortage-list removal, giving clinics and pharmacies more time to establish protocols. The PeptideBase directory lists 637 verified semaglutide providers vs 423 for tirzepatide as of May 2026 — a gap that reflects market maturity as much as current regulatory posture. Both numbers are lower than pre-2025 counts following enforcement actions against non-compliant compounders.

QWhat's the typical cost without insurance coverage?

Branded Wegovy and Zepbound both carry list prices in the range of $1,000–$1,300 per month without coverage. Insurance coverage varies significantly across commercial plans. Both manufacturers' patient assistance programs offer discounted or no-cost access for qualifying patients. These figures change frequently — verify current pricing with the dispensing pharmacy and your insurance plan directly.

---

Comparison at a glance

---

Related compounds

For patients seeking weight management support outside the GLP-1 pathway, AOD-9604 — a fragment of the growth hormone molecule — is researched for lipolytic properties with a different mechanism and lower regulatory complexity. Retatrutide, a triple agonist (GLP-1 + GIP + glucagon), is in Phase 3 trials with early data suggesting efficacy beyond both semaglutide and tirzepatide.

---

Educational information only — not medical advice. No dosing, protocol, or treatment advice is provided or implied.

Last reviewed: May 2026